[(Cp-R)M(CO)3] (M= Re or 99mTc) Conjugates for Theranostic Receptor Targeting

Can, Daniel; Schmutz, Paul; Sulieman, Samer; Spingler, Bernhard; Alberto, Roger

doi:10.2533/chimia.2013.267

Cited by 8 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The metal chosen for creating the model radiopharmaceutical complexes presented in this paper is rhenium, which is ideally suited due to its similarities to technetium. 9 In radiopharmacy technetium is used as a diagnostic agent utilizing the 99m Tc isotope which decays to release gamma radiation. 99m Tc is routinely used in thyroid, 10 heart, 11 kidney, 12 brain 13 and bone 14 imaging; moreover the isotope is investigated for selective cancer imaging.…”

Section: Introductionmentioning

confidence: 99%

Substitution reactivity and structural variability induced by tryptamine on the biomimetic rhenium tricarbonyl complex

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Substitution reactivity and structural variability induced by tryptamine on the biomimetic rhenium tricarbonyl complex

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Re compounds [15,[21][22][23]. Due to the small size of octahedral complexes based on the the fac-[M(CO) 3 ] + (M = Re and Tc) core considerably to the octahedral or square-pyramidal complexes of the corresponding metals in higher oxidation states, they are considered less likely to impact important characteristics of bio-molecules to which they are conjugated to [14,24].…”

Section: /188mentioning

confidence: 99%

Monomeric and dimeric complexes of pyrimidine-4,6-dicarboxylic acid with organometallic fac-[M(CO)3]+ (M = Re and 99mTc) core as radiopharmaceutical probes

Mukiza,

Habarurema,

Sezirahiga

et al. 2024

Preprint

View full text Add to dashboard Cite

The current study describes the synthesis of monomeric and dimeric complexes of pyrimidine-4,6-dicarboxylic acid (H2pmdc) ligand with the organometallic fac-[M(CO)3]+ (M = Re and 99mTc) core which are the model for future design of imaging, therapeutic and theranostic radiopharmaceuticals. Monomeric complexes [M(CO)3(OH2)(Hpmdc)] (M = Re (1) and 99mTc (2)) were formed from the reaction of H2pmdc with [Re(CO)5Br] and [99mTc(CO)3(OH2)3]+ in aqueous solution respectively. The reaction of [Re(CO)5Br] with H2pmdc in ethanol (EtOH) led to the monomeric complex [Re(CO)3(OH2)(etpmdc)] (3), where etpmdc− is 6-(ethoxycarbonyl)pyrimidine-4-carboxylate anion which was formed from the mono-esterification of H2pmdc in parallel with its coordination to the fac-[Re(CO)3]+ unit. Dimeric complex (Et3NH)2[(µ-pmdc)2(Re(CO)3)2 (4) was obtained from the reaction of [Re(CO)5Br] with H2pmdc in water with addition of triethylamine (Et3N) as supporting base. The chemical identification of 1, 3 and 4 was achieved by using 1HNMR, 13CNMR, IR, ESI-MS and elemental analysis. Complex 3 was furtherly identified by using single crystal X-ray crystallography. The structural similarities of 1 and 2 was assessed by coinjection in the HPLC with UV/Vis detection coupled with a γ-detector followed by comparison of retention times of the γ-peak of 2 and the UV-peak of 1 which allowed unambiguous identification of 2. Heterodinuclear 99mTc/Re complex [(µ-pmdc)2(Re(CO)3)(99mTc(CO)3)2)]2− (5) was formed by reacting H2pmdc with [99mTc(CO)3(OH2)3]+ and [Re(CO)5Br] in aqueous solution. In parallel, the reaction also yielded complexes 1 and 2. The formation of 5 was assessed by injection in the HPLC with UV/Vis detection coupled with a γ-detector which displayed the radiochemical peak with the corresponding UV peak equivalent to that of the homologous non-radioactive complex 4.

show abstract

“…29,34,50 The “matched-pair theory,” in which the Tc and Re isotopes are utilised for tandem therapeutic and diagnostic (theranostic) applications, has also become an attractive concept in the field of nuclear medicine. 52–54 This offers the possibility of developing 99m Tc agents for patient pre-selection and follow-up by diagnostic imaging and, thereafter, treatment with the corresponding 186/188 Re analogues.…”

Section: Why Radiorhenium?mentioning

confidence: 99%